Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia

Show simple item record

dc.identifier.uri Plagemann, Thomas Prenzler, Anne Mittendorf, Thomas 2017-02-23T13:12:54Z 2017-02-23T13:12:54Z 2011
dc.identifier.citation Plagemann, T.; Prenzler, Anne; Mittendorf, T.: Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. In: Health Economics Review 1 (2011), Nr. 1, S. 1-9. DOI:
dc.description.abstract Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders (calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in terms of binding of free phosphate. There are, however, a few disadvantages of the two groups. While the calcium-containing binders are associated with an increased risk of hypercalcaemia, which is dose dependent, calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from chronic kidney failure increases from year to year, as a result of increasing prevalence, there is a growing need for an alternative to existing phosphate binders. The study presented here therefore summarizes available information for the novel combination preparation OsvaRen® (calcium acetate/magnesium carbonate) as an alternative therapy to the calcium-free phosphate binder Renagel® (sevelamer-hydrochloride) and to calcium-containing preparations. The results of this systematic review showed that OsvaRen® is at least equally effective in the regulation of serum phosphate level as Renagel®. In particular, OsvaRen® shows no clinically relevant difference in terms of the control of the serum calcium levels compared to Renagel® and thereby does not increase the risk of a hypercalcaemia, in contrast to pure calcium-based phosphate binders. On the other hand, Renagel® therapy is much more frequently associated with gastrointestinal side-effects, a tendency to result in higher tablet burden for patients and high medication costs. The CALMAG study showed that OsvaRen® was at least as effective and safe in terms of controlling serum phosphate and serum calcium levels as Renagel® while, at the same time, resulting in about 80% lower costs. In addition, OsvaRen® offers a lower risk of hypercalcaemia and associated subsequent costs and is thereby also superior to pure calcium-containing phosphate binders. Because of the effectiveness and tolerability of calcium acetate/magnesium carbonate, OsvaRen® offers a clinically suitable and, at the same time, cost-effective therapeutic option in the therapy of hyperphosphataemia. eng
dc.description.sponsorship Fresenius Medical Care Deutschland GmbH
dc.language.iso eng
dc.publisher Heidelberg : Springer Verlag
dc.relation.ispartofseries Health Economics Review 1 (2011), Nr. 1
dc.rights CC BY 2.0 Unported
dc.subject aluminum hydroxychloride eng
dc.subject calci gry eng
dc.subject calcium eng
dc.subject calcium acetate eng
dc.subject calcium acetate plus magnesium carbonate eng
dc.subject calcium based phosphate binding agent eng
dc.subject calcium carbonate eng
dc.subject calciumacetat nefro eng
dc.subject calciumacetat prorenal am eng
dc.subject cc nefro eng
dc.subject dreisacarb eng
dc.subject lanthanum carbonate eng
dc.subject magnesium eng
dc.subject miscellaneous drugs and agents eng
dc.subject osvaren eng
dc.subject phos ex eng
dc.subject phosphate eng
dc.subject phosphate binding agent eng
dc.subject sevelamer eng
dc.subject sevelamer carbonate eng
dc.subject unclassified drug eng
dc.subject absence of side effects eng
dc.subject aluminum overload eng
dc.subject anemia eng
dc.subject blood vessel calcification eng
dc.subject calcium blood level eng
dc.subject cardiovascular disease eng
dc.subject cost benefit analysis eng
dc.subject cost effectiveness analysis eng
dc.subject drug cost eng
dc.subject drug efficacy eng
dc.subject drug safety eng
dc.subject drug tolerability eng
dc.subject gastrointestinal symptom eng
dc.subject human eng
dc.subject hypercalcemia eng
dc.subject hyperphosphatemia eng
dc.subject hypophosphatemia eng
dc.subject magnesium blood level eng
dc.subject medication compliance eng
dc.subject monotherapy eng
dc.subject osteomalacia eng
dc.subject patient compliance eng
dc.subject perception disorder eng
dc.subject phosphate blood level eng
dc.subject priority journal eng
dc.subject quality of life eng
dc.subject review eng
dc.subject risk factor eng
dc.subject risk reduction eng
dc.subject systematic review eng
dc.subject.ddc 330 | Wirtschaft ger
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia eng
dc.type Article
dc.type Text
dc.relation.issn 2191-1991
dc.bibliographicCitation.issue 1
dc.bibliographicCitation.volume 1
dc.bibliographicCitation.firstPage 1
dc.bibliographicCitation.lastPage 9
dc.description.version publishedVersion
tib.accessRights frei zug�nglich

Files in this item

This item appears in the following Collection(s):

Show simple item record


Search the repository


My Account

Usage Statistics